Darodipine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Darodipine
Accession Number
DB09234
Type
Small Molecule
Groups
Experimental
Description

Darodipine is a calcium channel blocker.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
N4AL7X96GL
CAS number
72803-02-2
Weight
Average: 371.393
Monoisotopic: 371.148120788
Chemical Formula
C19H21N3O5
InChI Key
QERUYFVNIOLCHV-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N3O5/c1-5-25-18(23)14-10(3)20-11(4)15(19(24)26-6-2)16(14)12-8-7-9-13-17(12)22-27-21-13/h7-9,16,20H,5-6H2,1-4H3
IUPAC Name
3,5-diethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OCC

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Darodipine.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Darodipine.Vet Approved
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Darodipine.Approved, Vet Approved
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Darodipine.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Darodipine.Approved
AmobarbitalThe metabolism of Darodipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Darodipine.Approved, Investigational
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Darodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Darodipine.Approved, Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Darodipine.Approved, Investigational
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Darodipine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Darodipine.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Darodipine.Approved
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Darodipine.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Darodipine.Experimental
BarbexacloneThe metabolism of Darodipine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Darodipine can be increased when combined with Barbital.Illicit
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Darodipine.Approved, Investigational
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Darodipine.Approved
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Darodipine.Approved, Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Darodipine.Experimental
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Darodipine.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Darodipine.Investigational
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Darodipine.Investigational
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Darodipine.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Darodipine.Approved
Calcium AcetateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Darodipine.Withdrawn
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Darodipine.Experimental
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Darodipine.Approved, Investigational
CaseinThe therapeutic efficacy of Darodipine can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Darodipine.Approved
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Darodipine.Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Darodipine.Approved
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Darodipine.Approved, Investigational, Vet Approved
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Darodipine.Approved, Investigational
CimetidineThe serum concentration of Darodipine can be increased when it is combined with Cimetidine.Approved, Investigational
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Darodipine.Approved
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Darodipine.Approved, Vet Approved
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Darodipine.Approved
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Darodipine.Investigational
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Darodipine.Approved, Investigational, Vet Approved
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Darodipine.Approved
DextroamphetamineThe risk or severity of hypotension can be increased when Dextroamphetamine is combined with Darodipine.Approved, Illicit
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Darodipine.Vet Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Darodipine.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Darodipine.Approved, Investigational
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Darodipine.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Darodipine.Approved, Vet Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Darodipine.Approved
EfavirenzThe serum concentration of Darodipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Darodipine.Approved
EpinephrineThe risk or severity of hypotension can be increased when Epinephrine is combined with Darodipine.Approved, Vet Approved
EscitalopramThe risk or severity of hypotension can be increased when Escitalopram is combined with Darodipine.Approved, Investigational
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Darodipine.Experimental
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Darodipine.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Darodipine.Approved, Investigational
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Darodipine.Approved, Investigational, Withdrawn
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Darodipine.Experimental
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Darodipine.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Darodipine.Approved, Investigational, Vet Approved
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Darodipine.Experimental
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Darodipine.Approved, Withdrawn
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Darodipine.Approved, Investigational
HexobarbitalThe metabolism of Darodipine can be increased when combined with Hexobarbital.Approved
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Darodipine.Approved
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Darodipine.Approved
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Darodipine.Withdrawn
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Darodipine.Approved
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Darodipine.Approved, Investigational
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Darodipine.Approved, Investigational
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Darodipine.Approved
LisdexamfetamineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Darodipine.Approved, Investigational
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Darodipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Darodipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Darodipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Darodipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Darodipine.Experimental
MethohexitalThe metabolism of Darodipine can be increased when combined with Methohexital.Approved
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Darodipine.Approved, Investigational
MethylphenobarbitalThe metabolism of Darodipine can be increased when combined with Methylphenobarbital.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Darodipine.Experimental
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Darodipine.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Darodipine.Approved, Investigational, Vet Approved
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Darodipine.Approved, Investigational
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Darodipine.Vet Approved
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Darodipine.Experimental
NafcillinThe therapeutic efficacy of Darodipine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Darodipine.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Darodipine.Approved
NefazodoneThe risk or severity of hypotension can be increased when Nefazodone is combined with Darodipine.Approved, Withdrawn
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Darodipine.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Darodipine.Approved, Investigational
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Darodipine.Experimental
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Darodipine.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Darodipine.Investigational
NitroprussideDarodipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Darodipine.Approved
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Darodipine.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Darodipine.Approved, Vet Approved
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Darodipine.Approved, Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Darodipine.Experimental
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Darodipine.Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Darodipine.Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Darodipine.Approved
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Darodipine.Approved, Investigational
PentobarbitalThe metabolism of Darodipine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PhenobarbitalThe metabolism of Darodipine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Darodipine.Approved
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Darodipine.Approved
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Darodipine.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Darodipine.Approved, Investigational, Vet Approved
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Darodipine.Approved
PrimidoneThe metabolism of Darodipine can be increased when combined with Primidone.Approved, Vet Approved
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Darodipine.Approved, Vet Approved
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Darodipine.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Darodipine.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Darodipine.Approved, Investigational
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Darodipine.Experimental
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Darodipine.Approved
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Darodipine.Approved, Investigational
RacepinephrineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Darodipine.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Darodipine.Experimental
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Darodipine.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Darodipine.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Darodipine.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Darodipine.Approved, Investigational
RisperidoneThe risk or severity of hypotension can be increased when Risperidone is combined with Darodipine.Approved, Investigational
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Darodipine.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Darodipine.Approved, Investigational, Vet Approved
SecobarbitalThe metabolism of Darodipine can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Darodipine.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Darodipine.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Darodipine.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Darodipine.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Darodipine.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Darodipine.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Darodipine.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Darodipine.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Darodipine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Darodipine.Approved
ThiamylalThe metabolism of Darodipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Darodipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Darodipine.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Darodipine.Approved, Withdrawn
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Darodipine.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Darodipine.Approved
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Darodipine.Approved, Vet Approved
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Darodipine.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Darodipine.Approved, Investigational, Vet Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Darodipine.Approved, Investigational
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Darodipine.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Darodipine.Experimental
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Darodipine.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Darodipine.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Darodipine.Investigational
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Darodipine.Approved
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Darodipine.Approved, Investigational
WortmanninThe therapeutic efficacy of Wortmannin can be increased when used in combination with Darodipine.Experimental
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Darodipine.Approved
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Darodipine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
51701
PubChem Substance
310265138
ChemSpider
46790
ChEMBL
CHEMBL2104154
Wikipedia
Darodipine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.258 mg/mLALOGPS
logP4.08ALOGPS
logP1.94ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)19.45ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area103.55 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity100.41 m3·mol-1ChemAxon
Polarizability37.67 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoxadiazoles. These are organic compounds containing a benzene fused to an oxadiazole ring (a five-membered ring with two carbon atoms, one nitrogen atom, and one oxygen atom).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzoxadiazoles
Sub Class
Not Available
Direct Parent
Benzoxadiazoles
Alternative Parents
Dihydropyridinecarboxylic acids and derivatives / Dicarboxylic acids and derivatives / Benzenoids / Vinylogous amides / Heteroaromatic compounds / Furazans / Enoate esters / Amino acids and derivatives / Enamines / Dialkylamines
show 5 more
Substituents
Benzoxadiazole / Dihydropyridinecarboxylic acid derivative / Dihydropyridine / Dicarboxylic acid or derivatives / Benzenoid / Hydropyridine / Azole / Heteroaromatic compound / Furazan / Vinylogous amide
show 20 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 23, 2015 10:27 / Updated on July 02, 2018 19:13